Novo Nordisk A/S
-
Health News
Here is Eli Lilly’s competitive edge in GLP-1 obesity drugs and Abbott’s secondary play
[ad_1] Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in…
Read More » -
Health News
Thinking about taking new weight loss drugs? These are the big health risk decisions that will follow
[ad_1] An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11,…
Read More » -
Health News
The pet drugs vets are now prescribing look a lot more like human medications
[ad_1] If you want to understand how different the human and animal medicine and vaccine industries have historically been, you…
Read More » -
Health News
Viking stock doubled Tuesday. Here’s where the next moves in the obesity space could come from
[ad_1] Anti-obesity drugmakers Novo Nordisk and Eli Lilly have a huge lead on their competition, but given the vast and…
Read More » -
Health News
The 11 GRANOLAS stocks power Europe to record highs, drawing Magnificent Seven comparisons
[ad_1] The German share price index DAX graph is pictured at the stock exchange in Frankfurt, Germany, January 19, 2024. …
Read More » -
Health News
Most employer health plans don’t cover new blockbuster weight loss drugs, but that’s going to change
[ad_1] Many U.S. companies are grappling with health insurance coverage issues for workers when it comes to GLP-1 drugs for…
Read More » -
Health News
The weight loss drug market may soon get more crowded. Here are the companies trying to enter the booming space
[ad_1] Still life of Wegovy an injectable prescription weight loss medicine that has helped people with obesity. It should be…
Read More » -
Business
Biden administration’s Medicare drug price negotiations will face major tests in 2024
[ad_1] Activists protest the price of prescription drug costs in front of the U.S. Department of Health and Human Services…
Read More » -
Health News
Obesity and Alzheimer’s drugs pack one-two punch to power Eli Lilly higher in 2024
[ad_1] Investor optimism for Eli Lilly ‘s diabetes and obesity treatments in 2023 lifted the stock to its seventh annual…
Read More » -
Health News
Oprah’s flip on weight loss drugs is a sign of what’s to come for the ‘Ozempic trade’ in 2024
[ad_1] For many struggling with obesity, new medications have been “a gift,” as Oprah Winfrey recently described it in declaring…
Read More »